Jorge Conde
speaker
469 appearances
4 recordings
1 series
first heard Sep 2025
last heard 2 Sep
Jorge Conde’s voice in public audio — every appearance, attributed to the second.
Trend
recordings per month · last 12 monthsRecordings per month over the last 12 months — 2 in all, peaking in Sep 2026 with 1.
Appearances
You and I have had we've known each other for a very long time.
Uh I won't depress you or me by saying how long you
So I've had the benefit of of of seeing the Moderna from the earliest days.
Yes.
And one thing that is true that was true then is true today is um you are well, first of all, you are an engineer at heart.
And um you have from the very, very beginning been obsessed with process, with operations, with being efficient.
Um and those things need to be absolutely true if you're going to attempt to do what you're trying to do here with personalized cancer vaccines and make a a you know a medicine for each individual patient.
precisely because in ninety percent of the cases there's no overlap uh uh uh in terms of the antigens.
Um
Can you talk us, uh talk walk us through a bit the operational lift that is required here that you've already had to do to even run the trial, but that you would have to do if you eventually commercialize um this product.
Sure.
Um and and let me maybe maybe one way to frame it is I think a lot of people think about the other big personalized therapy that exists in cancer is CAR T cell therapy, right?
And in that case.
the thing that in CART T cell therapy for folks that may not be familiar is this idea that you take a you take a patient's tumor um and then you take the patient's immune cells, you take them out of the body, and you essentially reprogram the immune cells um and and reengineer them to be reactive to the tumor and put them back into the patient.
And oversimplifying, of course.
Um, but that's, you know, CRT cell therapy in a in a very sort of uh in a simple nutshell.
In this case, you're doing in some ways things that are very similar, right?
You're t you're taking a piece of the tumor in that you have in the form of of a biopsy, presumably, um, and and and you're it trying to teach the um uh you're trying to sequence the tumor to generate a vaccine that is very specific uh uh to that patient's uh tumor.
How do you think about um essentially the vein to vein time?
Like what needs to be true from the moment you, you know, sort of see a patient and get access to the tumor to the moment that patient receives their personalized vaccine?
Showing 61–80 of 469 · page 4 of 24
← Previous
Next →